StemDAO
StemDAO
Stem Cell

The world of stem cell therapy has been held hostage for too long, buried under bureaucracy, patents, and pharma lobbying. ‍StemDAO is here to change that. We are on a mission to accelerate the development of cutting-edge stem cell therapies, free from the artificial constraints of outdated regulatory systems. By leveraging desci and global collaboration through token governance, we’re reclaiming stem cell medicine for the people. Join us in breaking down barriers, funding real innovation, and ensuring that life-altering therapies reach those who need them now, not decades from now.

Learn more:

Market Hypothesis

~3K

Number of stem cell clinics (US).

~60k Per Year

Global medical tourism volume in 2023.

2-3B$ Per Year

Global unregulated stem cell market.

Regenerative medicine is exploding, but stuck in red tape. We're building the protocol stack to get clinical-grade data and bring stem cell access to the people.


Stem cells, secretomes, and extracellular vesicles (EVs) are powerful tools for reversing tissue damage and age-related decline. Among these, stem cell-derived EVs, which are nano-sized carriers of proteins, RNAs, and lipids, offer a potent, scalable...

Research Focus Areas
Stem Cell EVs to Treat Aging

Stem Cell EVs to Treat Aging

We develop polarized MSC-derived EVs to target cognitive decline, skin and systemic aging, and soft tissue injuries. Our preclinical data show enhanced neurogenesis and cognitive function via intranasal delivery, and reduced senescence and inflammation in skin fibroblasts. Exosomes also show promise for lifespan extension.


StemDAO Clinic Network

StemDAO Clinic Network

We’re building a decentralized access layer for stem cell therapies. Our platform connects approved clinics worldwide with patients holding treatment vouchers via tokenized access. It includes patient onboarding, biomarker tracking, and post-treatment reporting.


StemDAO Data and Review

StemDAO Data and Review

A regulatory innovation to safely conduct trials outside legacy systems. Our dIRB framework enables community-governed approval of ethical, fast-track regenerative medicine protocols, backed by advisors, clinicians, and Web3 infrastructure.


Team & Community
Tomer Landsberger

Tomer Landsberger

PhD, Weizmann insitute of science, Gero.AI, VitaDAO

Scientist-entrepreneur and transhumanist. PhD Systems Immunology from the Weizmann Institute of Science, MSc in Theoretical Physics and Philosophy....

Ash Raziel

Ash Raziel

Last Question, Ark Reactor, Duke

Entrepreneur and operator, founded multiple VC backed startups in the biotech space designing bioreactors and producing gene and...

Shay Geula

Shay Geula

PhD, Weizmann institute, CatchMe therapeutics, Renewal Bio

Stem Cell & Aging Scientist, specialist in cellular and molecular biology. Co-founder of CatchMe Therapeutics & Renewal Bio,...

Gadi Turgeman

Gadi Turgeman

Prof, Ariel University

Ariel University PI specializing in stem cell applications for neurobehavioral disorders. Research spans mesenchymal stem cells, neurogenesis, and...

@stem_dao on 𝕏

Discord community

Telegram community

Project Roadmap
Q3 2025
Platform launch: public site, token utility, and governance portal — Onboard first 3 clinics and governance vote to greenlight first EV therapy project
Q4 2025
Finalize biomarker panel and patient protocol for EV trial — Governance vote to approve dIRB framework and reviewer cohort and first production run of polarized stem cell EVs.
Q1 2026
Data to DAO — First pre-clinical data delivered to DAO and first dIRB-approved protocol launched in clinic.
Value Capture Model

Value Capture — Building the Stack for Sovereign Biotech...

Value Capture Model Diagram
Recommended Reads
Stem cell-derived extracellular vesicles as senotherapeutics

Elsevier

Stem cell-derived extracellular vesicles as senotherapeutics


Therapeutic Potential of Extracellular Vesicles in Aging and Age-Related Diseases

MDPI

Therapeutic Potential of Extracellular Vesicles in Aging and Age-Related Diseases


Weighing up the evidence used by direct-to-consumer stem cell businesses

Cell.com

Weighing up the evidence used by direct-to-consumer stem cell businesses